We continue to have a strong commitment to medical research and the advancement of treatments for all conditions of eye diseases. If you or someone you know is interested in more information about our clinical research trials in Ophthalmology, please call 909-558-2233 or email the research coordinators Norlisha Borntrager, Rebecca Pereyra and Chelsea Lawson.

Current Clinical Trials

RETINA

  1. DRCR Genes: Genes in Diabetic Retinopathy Project. The goal of this project is to create a repository of at least 5000 participant’s blood to define factors that confer risk for development and progression of Diabetic Retinopathy and other retinal diseases and response to therapeutic intervention. Must be enrolled in a DRCR study to participate. PI: Dr. David Sierpina
  2. DRCR AF- A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening. This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening or center-involved diabetic macular edema (CI-DME) with vision loss through 4 years of follow-up in participants with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline.  PI: Dr. David Sierpina
  3. DRCR AM- Randomized trial comparing immediate versus deferred surgery for symptomatic Epiretinal Membrane. PI: Dr. Kakarla Chalam
  4. Samsara-Sing- A prospective multicenter clinical study of the implantable miniature telescope in patients with central vision Impairment associated with end-stage age-related macular degeneration (AMD) PI: Dr. Michael Rauser
  5. DRCR- AFA- Diabetic Retinopathy and changes in Lipid metabolism PI: Dr. David Sierpina
  6. DRCR AO- Home OCT- guided treatment versus treat and extend for the management of neovascular AMD PI: Dr. David Sierpina

CORNEA

  1. RGN-NK-302- A phase 3 multi-center randomized parallel double-masked, placebo controlled clinical study to assess the safety and efficacy of 0.1% RGN-259 ophthalmic solution for the treatment of Neurotrophic Keratopathy (SEER-2) PI: Dr. John Affeldt
  2. Claris Bio- CSB-C23-001- An open-label study comparing the safety and efficacy of two CSB-001 ophthalmic solution 0.1% dosing regimens in subjects with Limbal Stem Cell Deficiency PI: Dr. John Affeldt
  3. Claris Bio- CSB- C23-002-A Two-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects with Corneal Scars PI:  Dr. John Affeldt


PEDIATRIC STUDIES

  1. PEDIG ATS22: Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles plus Patching for Amblyopia in Children 3 to <13.  PI: Dr. Michael Rauser
     

Future Clinical Trials

RETINA

  1. Inflammasome Therapeutic: Non- randomized, open label, safety and efficacy study evaluating Kamuvudine-8 (K8) for the treatment of patients with Geographic Atrophy.  PI: Dr. Kakarla Chalam
  2. 4Dmolecular Therapeutics, Inc: A phase 3 randomized double masked active controlled trial of a single intravitreal injection of 4D-150 in adults with Macular Neovascularization secondary to Age Related Macular Degeneration (4FRONT-1) PI: Dr. Michael Rauser
  3. DRCR AP- A randomized clinical trial evaluating combination Faricimab + PRP vs. Vitrectomy + Endolaser for treatment of Proliferative Diabetic Retinopathy PI: Dr. David Sierpina

CORNEA

  1. Acelyrin- Thyroid Eye Disease- A phase 2b/3 randomized double blinded placebo-controlled study to evaluate the efficacy and safety of Lonigutamab in subjects with active Thyroid eye Disease. PI: Dr. Eman Hawy